ArticleFrontiers in oncology2025
Prognostic impact of CT-derived muscle-adipose index change in patients with inoperable esophageal squamous cell carcinoma undergoing chemoradiotherapy.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The muscle-adipose index (MAI), a novel nutritional parameter for assessing body composition, has emerged as a potential prognostic indicator. This study aimed to research MAI and its longitudinal changes before and after chemoradiotherapy (CRT) and to evaluate the prognostic implications of these changes in patients with inoperable esophageal squamous cell carcinoma (ESCC). Methods: This retrospective cohort included 180 ESCC patients treated with CRT (2020-2024). MAI was derived from CT-based quantification of skeletal muscle and subcutaneous adipose tissue at the third lumbar vertebra(L3). Baseline (preMAI), post-treatment (postMAI), and their longitudinal changes (ΔMAI) were analyzed. Optimal cutoff values for MAI imbalance were determined using X-tile software. Overall survival (OS) and progression-free survival (PFS) were assessed using Kaplan-Meier and Cox regression analyses. Results: Among 180 enrolled patients, 111 (61.7%) patients died during follow-up (median OS:23.0 months; median PFS:16.0 months).PreMAI and postMAI demonstrated statistically significant associations with OS (preMAI: HR = 5.934,95%CI=3.943-8.929, P<0.001; postMAI: HR = 9.123,95%CI=5.769-14.426, P<0.001) and PFS (preMAI: HR = 5.316, 95%CI=3.583-7.889, P<0.001; postMAI: HR = 8.008, 95%CI=5.213-12.303, P<0.001). The 0 group ( Conclusion: CT-derived MAI was a robust prognostic biomarker in ESCC. These findings highlighted the clinical utility of MAI for risk stratification and personalized therapeutic strategies in inoperable ESCC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.